Genmab A/S Current Liabilities
The Current Liabilities of Genmab A/S (GMAB.CO) as of Sep 26, 2026 is 676.92 M USD. In the previous year, Current Liabilities was 664.60 M USD — a change of 1.85% (higher).
Get this data via API
Financial Data API
Current Liabilities
676.92 MUSD
YoY
1.85%
Last updated:
The Genmab A/S Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 676.92 MUSD | +1.85% | |
| 664.60 MUSD | +39.73% | |
| 475.63 MUSD | -23.06% | |
| 618.14 MUSD | +112.08% | |
| 291.47 MUSD | -17.88% | |
| 354.93 MUSD | +33.68% | |
| 265.51 MUSD | +173.03% | |
| 97.24 MUSD | +258.93% | |
| 27.09 MUSD | -3.77% | |
| 28.15 MUSD | +39.15% | |
| 20.23 MUSD | +24.36% | |
| 16.27 MUSD | +14.49% | |
| 14.21 MUSD | -47.83% | |
| 27.24 MUSD | +47.77% | |
| 18.43 MUSD | -90.98% | |
| 204.45 MUSD | +47.46% | |
| 138.65 MUSD | -15.10% | |
| 163.31 MUSD | -1.22% | |
| 165.32 MUSD | +455.62% | |
| 29.75 MUSD | +86.96% | |
| 15.92 MUSD | +30.37% | |
| 12.21 MUSD | -3.49% | |
| 12.65 MUSD | -49.21% | |
| 24.91 MUSD | +197.63% | |
| 8.37 MUSD | +75.65% | |
| 4.76 MUSD | +1,348.02% | |
| 329,000.00USD | — |
Genmab A/S Stock analysis
Frequently Asked Questions about Genmab A/S stock
Current Liabilities of Genmab A/S is 676.92 M USD in 2026.
Current Liabilities of Genmab A/S changed from 664.60 M USD to 676.92 M USD, representing a 1.85% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Genmab A/S since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Genmab A/S historically and in real time.
Balance Sheet — Genmab A/S
All Key Metrics — Genmab A/S
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth